Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026
Key Highlights
- ➤CRB-913 60 mg delivered 5.0% mean weight loss at 12 weeks
- ➤All three CRB-913 doses achieved statistically significant weight loss versus placebo
- ➤60 mg cohort reduced waist circumference 3.94 cm and BMI 4.99%
- ➤CRB-913 AE-related discontinuation rate was 8.3% across cohorts
- ➤Corbus plans FDA discussions and is evaluating CRB-913 with GLP-1 therapies
Expert Statements
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus Pharmaceuticals
“We’re pleased to share the CANYON-1 trial data at ObesityWeek®. While the rise of incretin-based therapies has been remarkable, a significant number of people either do not adequately respond to or cannot tolerate these therapies, with more than 60% discontinuing treatment within the first year on these medicines”
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus Pharmaceuticals
“In the CANYON-1 trial, CRB-913 was safe and well tolerated while demonstrating clinically meaningful weight loss as an oral therapy via a distinct, non-incretin mechanism. We’re encouraged that CRB-913 has emerging potential as a novel therapeutic option for people living with obesity and look forward to future development.”
* CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateauing observed * Corresponding significant reductions were also seen in waist circumference and body mass index (BMI) * Treatment-emergent psychiatric adverse events (AEs) were infrequent, mostly mild, and in line with published GLP-1 data * No serious or severe psychiatric AEs were reported, including no cases of severe or serious suicidality or depression * Vomiting, nausea, and constipation occurred at lower rates and were milder than those reported in published studies of oral GLP-1s NORWOOD, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing new therapies in oncology and obesity, announced today that additional data from the CANYON-1 Phase 1b obesity study were presented in a poster at ObesityWeek® 2026.
Get started
Create a free account to read the full story.
